Icon Bioscience Announces Early Completion Of Patient Enrollment In Its Phase 3 Study Of IBI-10090; Drug Addresses Market Need For Long-Acting Treatment Of Inflammation Post Cataract Surgery

SUNNYVALE, Calif.--(BUSINESS WIRE)--Icon Bioscience, Inc., a specialty biopharmaceutical company focused on utilizing its Verisome® drug-delivery platform to develop unique intraocular eye-care therapeutics, today announced the completion of patient enrollment in its pivotal phase 3 study of IBI-10090, approximately four months ahead of projected timelines.

Help employers find you! Check out all the jobs and post your resume.